sosei group corp
(4565:Tokyo Stock Exchange)
Peter James Jonathan Bains
External Director, Member of Audit Committee and Member of Compensation Committee,Sosei Group Corporation
|Age||Total Calculated Compensation||This person is connected to 44 board members in 7 different organizations across 8 different industries.|
See Board Relationships
Mr. Peter James Jonathan Bains has been the Chief Executive Officer of Syngene International Ltd. since February 2, 2015. Mr. Bains serves as a Senior Advisor of Phase4 Partners Limited. Mr. Bains has been a Consultant specializing in supporting strategic growth opportunities in small- and medium-sized innovation-based life science companies since 2009. He has more than two decades of experience in the global pharmaceutical space encompassing strategic and operational ...
Kojimachi Tsuruya Hachiman BuildingPhone: 81 3 5210 3290
Tokyo, -- 102-0083
Fax: 81 3 5210 3291
Board Members Memberships*
Senior Advisor and Non-Executive Director
External Director, Member of Audit Committee and Member of Compensation Committee
Chief Executive Officer and Director
Non Executive Chairman, Chairman of Corporate Social Responsibility (CSR) Committee and Member of Audit Committee
The University of Sheffield
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Steven M. Klosk||Chief Executive Officer, President and Director|
|Timothy J. Miller Ph.D.||Chief Executive Officer, President and Director|
Abeona Therapeutics Inc.
|Stephen Edward Foots||Group Chief Executive, Executive Director, Chairman of Group Executive Committee, Member of Nomination Committee, Member of Routine Business Committee, Member of Group Safety, Health & Environment Steering Committee, Member of Finance Committee and Member of Risk Management Committee|
Croda International plc
|Murali Krishna Prasad Divi M. Pharm, Ph.D.||Chairman, Managing Director and Member of Corporate Social Responsibility Committee|
Divi's Laboratories Limited
|9.0M||Compensation as of Fiscal Year 2014.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.